Skip to main content


8 result(s) for 'Arsene Mekinian' within Arthritis Research & Therapy

Page 1 of 1

  1. From this retrospective study, we aimed to (1) describe the prevalence and characteristics of non-criteria features in primary antiphospholipid syndrome (p-APS) and (2) determine their prognostic value.

    Authors: Alexis F. Guédon, Jennifer Catano, Laure Ricard, Charlotte Laurent, Claire de Moreuil, Geoffrey Urbanski, Sophie Deriaz, Grigorios Gerotziafas, Ismail Elalamy, Alexandra Audemard, Francois Chasset, Sonia Alamowitch, Jérémie Sellam, François Maillot, Jean Jacques Boffa, Ariel Cohen…
    Citation: Arthritis Research & Therapy 2022 24:33
  2. Sugiyama et al. recently described in “Latent class analysis of 216 patients with adult-onset Still’s disease,” baseline characteristics, laboratory tests, treatment, relapse, and death of adult-onset Still’s ...

    Authors: Marion Delplanque, Arsène Mekinian and Sophie Georgin-Lavialle
    Citation: Arthritis Research & Therapy 2022 24:285
  3. To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK).

    Authors: Arsene Mekinian, David Saadoun, Eric Vicaut, Sara Thietart, Bertrand Lioger, Patrick Jego, Alexandre Bleibtreu, Nicolas Limal, Jerome Connault, Jacques-Eric Gottenberg, Pauline Lhorte, Jean Pierre Bertola, Juliette Delforge, Nicole Ferreira-Maldent, Antoinette Perlat, Zohra Talib…
    Citation: Arthritis Research & Therapy 2020 22:218
  4. To assess the efficacy and tolerance of tocilizumab (TCZ) in giant cell arteritis (GCA) patients over 80.

    Authors: Hubert de Boysson, Maelle Le Besnerais, Félix Blaison, Aurélie Daumas, Pierre-André Jarrot, François Perrin, Nathalie Tieulié, Alexandre Maria, Pierre Duffau, Bruno Gombert, Maxime Samson, Olivier Espitia, Marc Lambert, Arsène Mékinian and Achille Aouba
    Citation: Arthritis Research & Therapy 2021 23:143
  5. Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting tha...

    Authors: Emmanuel Ledoult, Maxime Morelle, Michael Soussan, Arsène Mékinian, Hélène Béhal, Vincent Sobanski, Eric Hachulla, Damien Huglo, Noémie Le Gouellec, Martine Remy-Jardin, Clio Baillet and David Launay
    Citation: Arthritis Research & Therapy 2021 23:76
  6. Data on survival and prognosis factors in incident cohorts are scarce in systemic sclerosis (SStc). To describe survival, standardized mortality ratio (SMR), and prognosis factors in systemic sclerosis (SSc), ...

    Authors: M. R. Pokeerbux, J. Giovannelli, L. Dauchet, L. Mouthon, C. Agard, J. C. Lega, Y. Allanore, P. Jego, B. Bienvenu, S. Berthier, A. Mekinian, E. Hachulla and D. Launay
    Citation: Arthritis Research & Therapy 2019 21:86
  7. Systemic sclerosis (SSc) is a severe and highly heterogeneous disease. The modified Rodnan skin score (mRSS) is a widely used tool for the assessment of the extent and degree of skin thickness. This study aime...

    Authors: Emmanuel Ledoult, David Launay, Hélène Béhal, Luc Mouthon, Grégory Pugnet, Jean-Christophe Lega, Christian Agard, Yannick Allanore, Patrick Jego, Anne-Laure Fauchais, Jean-Robert Harlé, Sabine Berthier, Achille Aouba, Arsène Mekinian, Elisabeth Diot, Marie-Elise Truchetet…
    Citation: Arthritis Research & Therapy 2020 22:30
  8. Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The importance of monitoring subjective measures of functioning and disability, such as the Health Assessment Questionnaire-Dis...

    Authors: Yannick Allanore, Sylvie Bozzi, Augustin Terlinden, Doerte Huscher, Caroline Amand, Christina Soubrane, Elise Siegert, László Czirják, Patricia E. Carreira, Eric Hachulla, Elisabetta Zanatta, Mengtao Li, Paolo Airò, Fabian A. Mendoza, Edoardo Rosato and Oliver Distler
    Citation: Arthritis Research & Therapy 2020 22:257

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2022 Speed
    9 days submission to first editorial decision for all manuscripts (Median)
    149 days submission to accept (Median)

    2022 Usage 
    17,226 Altmetric mentions